Aura Biosciences reported Q4 and FY 2025 financial results, highlighting accelerated Phase 3 enrollment with topline data expected in 2H 2027 and a cash runway extending into Q1 2027.
Key takeaways
The Company reported a net loss of $106.2 million for the full year ended December 31, 2025, compared to $86.9 million in the prior year.
Cash and cash equivalents and marketable securities totaled $144.2 million as of December 31, 2025.
The Company expects to complete Phase 3 CoMpass trial enrollment by mid-2026, with topline data anticipated in the second half of 2027.
Research and development expenses increased to $90.3 million for the full year 2025, up from $73.3 million in 2024.
Initial 3-month clinical data from the Phase 1b/2 NMIBC trial is expected in mid-2026.